ArticleAdvances in therapy2026

Real-World Use of Abrocitinib for Moderate-to-Severe Atopic Dermatitis in the United States Based on Electronic Health Records and Administrative Claims.

Raj Chovatiya et al.PubMed ↗Publisher ↗

No numbers read from the abstract.